NDAORALTABLETPriority Review
Approved
Jun 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
Drug Shortage Active
PRIFTIN is currently in shortage. Reason: Available. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.
PRIFTIN (rifapentine) by Sanofi. Approved for rifamycin antimycobacterial [epc]. First approved in 1998.
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRIFTIN (rifapentine) is an oral rifamycin antimycobacterial agent used to treat tuberculosis infections. It works by inhibiting bacterial RNA polymerase, disrupting mycobacterial protein synthesis. The drug is administered as tablets and represents a key option in TB treatment regimens.
$0.42MPart D
LOE ApproachingProduct approaching loss of exclusivity with modest Part D utilization (2,228 claims), indicating limited commercial team expansion and focus on maximizing remaining protected market share.
Mechanism of Action
Pharmacologic Class:
Rifamycin Antimycobacterial
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV
Started Oct 2026
144 enrolled
Tuberculosis
Rifapentine-Based Shorter Regimens for Tuberculosis and TB Infection in Kazakhstan
Started Jul 2026
350 enrolled
TuberculosisTuberculosis Infection, LatentTuberculosis, Pulmonary, Drug Sensitive
Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis
Started Feb 2024
30 enrolled
HIV-associated Tuberculosis
Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV
Started Jan 2024
252 enrolled
HIV SeropositivityPregnancyTuberculosis Infection
Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients
Started Jul 2023
1,000 enrolled
HIV SeropositivityTuberculosisHousehold Contact
Worked on PRIFTIN at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.